Intensive Care Unit, Hospital Privado de Comunidad, Mar del Plata, Argentina.
Escuela Superior de Medicina, Universidad Nacional de Mar del Plata, Mar del Plata, Argentina.
Crit Care. 2022 Jan 7;26(1):16. doi: 10.1186/s13054-021-03881-2.
In patients with COVID-19-related acute respiratory failure (ARF), awake prone positioning (AW-PP) reduces the need for intubation in patients treated with high-flow nasal oxygen (HFNO). However, the effects of different exposure times on clinical outcomes remain unclear. We evaluated the effect of AW-PP on the risk of endotracheal intubation and in-hospital mortality in patients with COVID-19-related ARF treated with HFNO and analyzed the effects of different exposure times to AW-PP.
This multicenter prospective cohort study in six ICUs of 6 centers in Argentine consecutively included patients > 18 years of age with confirmed COVID-19-related ARF requiring HFNO from June 2020 to January 2021. In the primary analysis, the main exposure was awake prone positioning for at least 6 h/day, compared to non-prone positioning (NON-PP). In the sensitivity analysis, exposure was based on the number of hours receiving AW-PP. Inverse probability weighting-propensity score (IPW-PS) was used to adjust the conditional probability of treatment assignment. The primary outcome was endotracheal intubation (ETI); and the secondary outcome was hospital mortality.
During the study period, 580 patients were screened and 335 were included; 187 (56%) tolerated AW-PP for [median (p25-75)] 12 (9-16) h/day and 148 (44%) served as controls. The IPW-propensity analysis showed standardized differences < 0.1 in all the variables assessed. After adjusting for other confounders, the OR (95% CI) for ETI in the AW-PP group was 0.36 (0.2-0.7), with a progressive reduction in OR as the exposure to AW-PP increased. The adjusted OR (95% CI) for hospital mortality in the AW-PP group ≥ 6 h/day was 0.47 (0.19-1.31). The exposure to prone positioning ≥ 8 h/d resulted in a further reduction in OR [0.37 (0.17-0.8)].
In the study population, AW-PP for ≥ 6 h/day reduced the risk of endotracheal intubation, and exposure ≥ 8 h/d reduced the risk of hospital mortality.
在 COVID-19 相关急性呼吸衰竭(ARF)患者中,清醒俯卧位(AW-PP)可降低接受高流量鼻氧(HFNO)治疗的患者插管的需求。然而,不同暴露时间对临床结局的影响尚不清楚。我们评估了在接受 HFNO 治疗的 COVID-19 相关 ARF 患者中,AW-PP 对气管插管风险和住院死亡率的影响,并分析了不同暴露时间对 AW-PP 的影响。
这是一项在阿根廷 6 个中心的 6 个 ICU 进行的多中心前瞻性队列研究,连续纳入 2020 年 6 月至 2021 年 1 月需要 HFNO 的确诊 COVID-19 相关 ARF 患者,年龄>18 岁。在主要分析中,主要暴露是至少每天 6 小时的清醒俯卧位,与非俯卧位(NON-PP)相比。在敏感性分析中,暴露基于接受 AW-PP 的小时数。逆概率加权倾向评分(IPW-PS)用于调整治疗分配的条件概率。主要结局是气管插管(ETI);次要结局是住院死亡率。
在研究期间,对 580 名患者进行了筛选,其中 335 名患者入选;187 名(56%)患者耐受 AW-PP,每天[中位数(p25-75)]12 小时(9-16 小时),148 名(44%)作为对照组。在所有评估的变量中,IPW-倾向分析的标准化差异均<0.1。调整其他混杂因素后,AW-PP 组 ETI 的比值比(95%CI)为 0.36(0.2-0.7),随着 AW-PP 暴露的增加,比值比逐渐降低。AW-PP 组每天≥6 小时的住院死亡率的调整比值比(95%CI)为 0.47(0.19-1.31)。每天俯卧位暴露≥8 小时可进一步降低比值比[0.37(0.17-0.8)]。
在研究人群中,每天≥6 小时的 AW-PP 可降低气管插管风险,每天≥8 小时的暴露可降低住院死亡率。